Speaker Profile
Ph.D., CEO and Co-Founder, Hepta
Biography
Hamed Amini is Co-Founder and CEO of Hepta, an AI-native liquid biopsy company building the diagnostic and data platform for chronic disease, beginning with MASH. Hepta decodes cell-free DNA methylation signals in blood to deliver tissue-level insight without biopsy, powered by LiquidTransformer, a transformer AI architecture purpose-built for liquid biopsy in chronic disease.
Hamed founded Hepta in 2022 after more than a decade at the forefront of genomics and diagnostics. He was a founding team member at GRAIL, where he led work across technology and product development and translational strategy, and played a pivotal role in developing and launching Galleri, GRAIL's flagship multi-cancer early detection test. Earlier, he was a scientist in Illumina's research division, working at the forefront of next-generation sequencing technologies.
He holds a Ph.D. in Biomedical Engineering from UCLA and a B.Sc. in Mechanical Engineering from Sharif University of Technology.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins
PMWC Award Ceremony
• Rebecca Fitzgerald, University of Cambridge (Luminary)
• Mary-Claire King, University of Washington (Pioneer)
• Nickolas Papadopoulos, Johns Hopkins (Pioneer)
Featured Speakers
• Mary-Claire King, University of Washington
• Rebecca Fitzgerald, University of Cambridge
• Nickolas Papadopoulos, Johns Hopkins
• Victor Velculescu, Johns Hopkins
• Phil Castle, NIH
• Elad Ziv, UCSF
• Ash Alizadeh, Stanford
• Hamed Amini, Hepta
• Becky Taub, Madrigal Pharmaceuticals
• Trevor Pugh, University of Toronto
• Doga Gulhan, Harvard
• Pranav Rajpurkar, Harvard
• Chris Douville, Johns Hopkins
• Sylvia Katina Plevritis, UCSF
In Precision Medicine, Almost All Diseases Are Genetically Rare
A genetics-first keynote framing risk, prevention, and actionability.
The Reckoning
What the first wave of early detection got right and wrong.
The End of One Size Fits All
Risk-stratified screening, high-risk populations, and single-cancer tests.
Treating Disease at the Earliest Stage
Where detection and therapeutic interception begin to converge.
Pre-Cancer Detection & the Liver Disease Frontier
cfDNA and clinical action across the liver-disease-to-cancer continuum.
AI Across Multimodal Signals
Fragmentomics, methylation, imaging, pathology, and integration: hype versus real science.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
